India Lymphedema Treatment Market to Grow at a CAGR of 12.29% to reach US$ 1,511.06 million from 2022 to 2030

The India lymphedema treatment market size is projected to grow from US$ 926.65 million in 2022 to US$ 1,511.06 million by 2030; the market is estimated to record a CAGR of 12.29% during 2022–2030.

Market Insights and Analyst View:

Lymphedema refers to tissue swelling caused by an accumulation of protein-rich fluid, which is drained through the body's lymphatic system. It most commonly affects the arms or legs but can also occur in the chest wall, abdomen, neck, and genitals. Lymph nodes are an essential part of the lymphatic system. Lymphedema is largely caused due to the consequence of several cancer treatments. These include prostate, head and neck, and pelvic cancers such as those in bladder, testicles, ovaries, uterus, or cervix, along with lymphoma and melanoma. The swelling may occur on the part of the body that is treated. For instance, treating tumors in the belly or pelvis via radiation or surgery may cause swelling in the groin, genitals, belly, and one or both legs. Swelling in the face, eyes, or mouth can be caused by treatment for head & neck cancer.

Growth Drivers:

Prevalence of Lymphatic Filariasis

Lymphatic filariasis (LF) continues to be a significant public health challenge in India. This vector-borne parasitic disease is extremely painful and disfigures the body parts causing severe disability, resulting in a condition called or elephantiasis. With over 40% of global LF cases found in India, it is a major threat to the country.

Approximately 640 million people in India are at risk of contracting the disease. LF has been reported in 336 districts across 20 States/Union Territories in India. 90% of the LF burden in India rests upon eight tropical states, including Uttar Pradesh, Bihar, Jharkhand, West Bengal, Chhattisgarh, Maharashtra, Odisha, and Madhya Pradesh.

According to National Disease Modelling Consortium stats, a total of 525,440 lymphedema cases were reported in India in 2021. Most lymphedema cases were reported from Bihar, Uttar Pradesh, Odisha, and Telangana. Furthermore, as per the news published in The Times of India, in February 2023, four cases of lymphedema were detected in Ahmedabad. In addition, 16 cases of lymphedema were detected in Tumakuru district in Karnataka from January 2022 to April 2022. Of these, the infection was majorly found in migrant workers from Bihar, Odisha, Uttar Pradesh, and Vijayapura district of Karnataka.

Thus, the rising number of lymphatic filariasis eventually drives the lymphedema treatment market in India.

Adverse Effects of Cancer Treatment

Cancer and its treatments, such as surgery and radiation therapy, may sometimes change, block, or interrupt the flow of lymph fluid across the lymphatic system. When edema develops from a build-up of lymphatic fluid, it is referred to as lymphedema. This abnormal collection of fluid causes swelling in specific areas of the body, most often in the arms or legs. If untreated, lymphedema may lead to decreased function and mobility in the affected limb, skin issues, pain and discomfort, and other complications. An accumulation of protein-rich lymph fluid may lead to increased swelling, hardening of the tissue, and infection.

Lymphedema is most often associated as a side effect of breast cancer. Breast cancer patients are majorly at risk of developing lymphedema because axillary lymph nodes in the armpit near the breast may be removed or damaged by breast cancer surgery, radiation therapy, or a combination of cancer treatments. Lymphedema may also result from treatment for prostate cancer, gynecological cancers, lymphoma, melanoma, or other cancers. The more lymph nodes are removed or damaged, the higher the risk of developing lymphedema.

As per Globocan 2020 stats, nearly 178,361 cases were found in India, and approximately 90,408 died from the disease. The most general complication of breast cancer treatment is lymphedema. Moreover, as per the consensus coordinated by the Division of NCD Indian Council of Medical Research 2022, prostate cancer appears to be a growing problem in males in India. The incidence of prostate cancer has been steadily increasing in recent years. As per the NCDIR database, prostate cancer features among the top 10 cancers in urban cancer registries of Bengaluru, Delhi, Bhopal, and Mumbai. There were 37,416 reported prostate cancer cases in 2016 in India, which increased to 41,532 in 2020. As per the same source, prostate cancer incidence is expected to increase to over 47,000 cases by 2025.

Thus, the rising incidence of cancer cases, especially breast and prostate cancer, prompting radiation therapy and surgeries for treatment propel the lymphedema treatment market in India.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

India Lymphedema Treatment Market: Strategic Insights

Market Size Value in	US$ 926.65 million in 2022
Market Size Value by	US$ 1,511.06 million by 2030
Growth rate	CAGR of 12.29% from 2022 to 2030
Forecast Period	2022-2030
Base Year	2022

Mrinal

Have a question?

Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

 Speak to Analyst

Report Segmentation and Scope:

The “India Lymphedema Treatment Market” is segmented on the basis of condition type, treatment type, and end user. Based on condition type, the market is segmented into primary lymphedema and secondary lymphedema. In terms of treatment type, the India lymphedema treatment market is segmented into compression devices and bandaging, drug therapy, physiological procedure, debulking procedure, and others. The physiological procedures segment is further segmented into lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT). The debulking procedures segment is sub-segmented into liposuction, surgical debulking, and others. Based on end user, the market is segmented into hospitals, clinics, clinical research organizations (CROs), and others.

Segmental Analysis:

The India lymphedema treatment market, by condition type, is segmented into primary lymphedema and secondary lymphedema. The secondary lymphedema segment held a larger share of the market in 2022. The primary lymphedema segment is anticipated to register a higher CAGR during 2022–2030. Secondary lymphedema's significant share is usually attributed to cancer-related treatment, which is a prominent cause of secondary lymphedema. Primary lymphedema is a rare chronic pathology associated with constitutional abnormalities of the lymphatic system. For instance, the Frontiers S.A. report states that primary lymphedema can appear at age 35 and is also referred to as lymphedema tarda. Additionally, the incidence of primary lymphedema is low, affecting 1 in 100,000 people worldwide. Primary lymphedema is also strongly linked to acquired lymphedema and has genetic mutations causing primary lymphedema. For example, breast cancer patients carrying acquired lymphedema have higher genetic variation, called single nucleotide polymorphisms (SNPs), in the same genes causing primary lymphedema. Such factors positively influence the overall growth of the segment during the analysis period.

India Lymphedema Treatment Market, by Condition Type– 2022 and 2030

Based on treatment type, the India lymphedema treatment market is segmented compression devices and bandaging, drug therapy, physiological procedure, debulking procedure, and others. The physiological procedures segment is further segmented into lymphovenous anastomosis (LVA) and vascularized lymph node transfer (VLNT). The debulking procedures segment is sub-segmented into liposuction, surgical debulking, and others. The compression devices and bandaging segment held the largest share of the market in 2022. The physiological procedure segment is expected to register the highest CAGR in the market during 2022–2030. This is mainly due to the appropriate treatment procedures performed on lymphedema patients through LVA and VLNT. These two procedures are appropriate treatment options for patients suffering from lymphedema. Surgical techniques of lymphedema management are split into two parts: physiologic therapy and ablative therapy. Physiologic surgical techniques are microsurgical procedures fostering the physiologic drainage of lymphatic fluid through the anastomosis of lymphatic vessels with the venous system or incorporating a functional lymph node in the region of ablative treatment. According to the NCBI report, physiologic procedures are most effective in the early stages of lymphedema; adding ablative therapy can also render them effective therapeutic options for late-stage lymphedema.

Based on end user, the India lymphedema treatment market is segmented into hospitals, clinics, clinical research organizations (CROs), and others. The hospital segment held the largest share of the market in 2022 and is anticipated to register the highest CAGR in the market during 2022–2030 due to many lymphedema procedures being performed in the hospitals and the launch of innovative products by prominent players targeting hospitals for maximum utilization. In September 2020, Paul Hartmann partnered with Apollo Hospitals Group in India and West China Hospitals with a foremost focus on the surgery of wound care clinics and ambulances, medical training, and products and services. Such strategic steps allow companies to expand their product portfolio in developed markets. The hospital segment accounts for the maximum share of the overall lymphedema treatment market. This is mainly due to the growing adoption of minimally invasive surgeries in hospitals and the uptake of advanced imaging modalities for treating lymphedema. Additionally, surgeries are performed in hospitals for treating lymphedema. For example, at the University of Michigan, plastic surgeons and occupational therapists work together to determine the optimal treatment program for patients suffering from illness. For instance, the Penn Medicine report states that about 60% of the patients who underwent lymphedema treatment procedures in hospitals revealed clear improvement. Furthermore, favorable reimbursement policies supporting hospital lymphatic treatment support the overall market growth. For example, the growing awareness of lymphedema as an expensive preventable complication following oncology surgery eliminates the barriers between the medical coverage for therapeutic and prophylactic procedures among patients, hospitals, and the healthcare systems.

Country Analysis:

Radiation due to radiotherapy heightens the risk of lymphedema by directly injuring lymphatic vessels with subsequent reduction to the carrying capacity of the lymphatic vessels. As per an article published in the National Center for Biotechnology Information (NCBI), "Cancer incidence estimates for 2022 and projection for 2025: Result from National Cancer Registry Programme, India," the number of cancer cases in India was estimated to be 1,461,427 in 2022. In India, 1 in 9 people is likely to develop cancer in their lifetime. Lung and breast were the leading cancer sites in males and females, respectively. As per Globocan 2020 report, breast cancer is the most common cancer in India. There were 178,361 (13.5%) cases of breast cancer in India in 2020. This is likely to demand radiotherapy in India. As per the same report, 72,510 (5.5%) new cases of lung cancer, 135,929 (10.3%) cases of lip and oral cavity cancer, 123,907 (9.4%) cases of cervix uteri cancer, 65,358 (4.9%) cases of colorectum cancer, and 748,348 (56.5%) cases of other cancers were reported in India. Therefore, the growing usage of radiotherapy to treat cancer and the high prevalence of cancer are driving the growth of the India lymphedema treatment market.

The prevalence of chronic diseases such as cardiovascular diseases (CVD) and stroke, rising geriatric population, lifestyle diseases, and the high prevalence rate of obesity in India are among the other factors driving the growth of the market. As per the World Heart Federation, CVDs account for 60% of total adult deaths in India. Addiction to smoking tobacco and an increase in alcohol consumption are among the factors resulting in CVD-related risks in Indian adults (i.e., nearly 15% of the population). According to the Indian Stroke Association, 1.8 million people suffer from stroke in India annually. Also, awareness about stroke is less, and people living in rural areas are not aware of neurovascular diseases. Lymphedema can also be a result of heart strain. This occurs when the heart has to work harder to pump and circulate blood throughout the body, including the affected limb. Therefore, these factors are anticipated to spur the India lymphedema treatment market in this region.

Industry Developments and Future Opportunities:

Various initiatives taken by key players operating in the India lymphedema treatment market are listed below:

1. KOB GmbH launched its two products at MEDICA Trade Fair 2022. With this 2-component system, the company expanded its product portfolio of compression bandages. VisioCompress2 Lite is used when a lower compression pressure is required. Like the proven VisioCompress2 multi-layer system, VisioCompress2 Lite consists of a padding and permanently elastic non-woven bandage.

Competitive Landscape and Key Companies:

Essity AB, Lympha Press USA Ltd, AIROS Medical Inc, 3M Co, Bio Compression Systems Inc, Lohmann & Rauscher GmbH & Co KG, Huntleigh Healthcare Ltd, Dynamic Techno Medicals Pvt Ltd, Medi GmbH & Co KG, Datt Mediproducts Pvt Ltd, Smith & Nephew Plc, SIGVARIS Management AG, and Tactile Systems Technology Inc are the prominent India lymphedema treatment market companies. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide.